Details for Patent: 7,612,073

Which drugs does patent 7,612,073 protect, and when does it expire?

Patent 7,612,073 protects KUVAN and is included in two NDAs.

Protection for KUVAN has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-seven patent family members in twenty-two countries.

Summary for Patent: 7,612,073

Title:	Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
Abstract:	The present invention is directed to treatment methods of administering tetrahydrobiopterin, including in oral dosage forms, in intravenous formulations, and with food. Also disclosed herein are biopterin assays for measuring the amount of biopterin and metabolites of biopterin in a sample.
Inventor(s):	Oppenheimer; Daniel I. (Castro Valley, CA), Dorenbaum; Alejandro (Mill Valley, CA)
Assignee:	Biomarin Pharmaceutical Inc. (Novato, CA)
Application Number:	12/329,838
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,612,073
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 7,612,073

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Biomarin Pharm	KUVAN	sapropterin dihydrochloride	POWDER;ORAL	205065-001	Dec 19, 2013	AB	RX	Yes	Yes					Y
Biomarin Pharm	KUVAN	sapropterin dihydrochloride	POWDER;ORAL	205065-002	Oct 27, 2015	AB	RX	Yes	No					Y
Biomarin Pharm	KUVAN	sapropterin dihydrochloride	TABLET;ORAL	022181-001	Dec 13, 2007	AB	RX	Yes	Yes					Y

International Family Members for US Patent 7,612,073

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2008240259
Australia	2008347005
Brazil	PI0809470